|
Department of
Biochemistry
WIlliam P. Petros, Pharm.D., FCCP
St Jude Children’s Research Hospital,
Post-Doctoral Fellow
in Pharmacometrics/Immunotherapy (1987-1990)
Graduate Training - Philadelphia College of Pharmacy & Science,
Pharm.D. (1987) Tampa VA Medical Center, Hospital Pharmacy
Residency (1983-1984)
Undergraduate Training - West Virginia University School of
Pharmacy, B.S. Pharmacy (1983)
Associate Professor for Anti-Cancer Drug Development,
Mary Babb Randolph Cancer Center
Department of Biochemistry
Department of Basic Pharmaceutical Sciences
West Virginia University
Robert C. Byrd Health Sciences Center
P.O. Box 9530
Morgantown, WV 26506-9350
Phone: (304) 293-0495
Fax: (304) 293-4667
Email: wpetros@hsc.wvu.edu
Professional Memberships:
American Association for Cancer Research
American Society of Clinical Oncology
Mary Babb Randolph / West Virginia University Cancer Center
Duke Comprehensive Cancer Center
American College of Clinical Pharmacy
Research Interests:
Clinical drug development in oncology,
Pharmacokinetics and pharmacodynamics of new anti-cancer agents,
Clinical pharmacology of hematopoietic growth factors,
Pharmacogenomics
Selected References:
- Petros WP , Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ,
Colvin OM, Peters WP, Jones RB, Hall J, Marks J. Associations
between variants in several drug metabolism genes, chemotherapy
pharmacokinetics and clinical anti-cancer response. In press, J Clin
Oncol.
- Petros WP & Evans WE. Pharmacogenomics in cancer therapy: is
host genome variability important? Trends Pharm Sci 2004;25:457-464.
- Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros
WP , Garbriel D, Serody J, Kirby S, Wiley J. Intra-individual
variability in busulfan pharmacokinetics in patients undergoing a
bone marrow transplant: Assessment of a test dose and first dose
strategy . Anti-Cancer Drugs 2004;15:453-459.
- Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS,
Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP ,
Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI. . A phase
I trial of preoperative 5-fluorouracil plus eniluracil and radiation
for locally advanced or unresectable adenocarcinoma of the rectum
and colon. Int J Radiat Oncol Biol Phys 2004;58:779-85.
- Cheng TY, Grubbs E, Abdul-Wahab O, Leu SY, Hung CF, Petros W ,
Aloia T, Fedrau R, Pruitt S, Colvin M, Friedman H, Tyler D. Marked
variability of melphalan plasma drug levels during regional
hyperthermic isolated limb perfusion. Am J Surg. 2003
Nov;186(5):460-7.
- Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M,
Jesberger J, Rafie N, OvermoyerB, Makkar V, Stambler B, Taylor A,
Waas J, Lewin J, McCrae KR, Remick SC. A Phase I Pharmacokinetic and
Translational Study of the Novel Vascular Targeting Agent
Combretastatin A4 Phosphate (CA4P) on a Single-Dose Intravenous
Schedule in Patients with Advanced Cancer. Cancer Res
2002;62:3408-3416.
- Petros WP , Broadwater G, Berry D, Jones RB, Vredenburgh JJ,
Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high-dose
cyclophosphamide, cisplatin and carmustine pharmacokinetics with
response, toxicity and dosing weight in patients with primary breast
cancer. Clin Cancer Res 2002;8:698-705.
- Rizzieri D, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM,
Petros WP , Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R,
Hurwitz H, Moore JO. Phase I evaluation of continuous-infusion
gemcitabine with mitoxantrone for relapsed or refractory acute
leukemia. J Clin Oncol 2002;20:674-679.
- Martell RE, Peterson B, Cohen HJ, Petros W, Rai KR, Larson R,
Schiffer C, Elias L, Sheperd L, Hurwitz HI. Analysis of age,
estimated creatinine clearance and pretreatment hematologic
parameters as predictors of fludarabine toxicity in patients treated
for chronic lymphocytic leukemia: A CALGB (9011) coordinated
Intergroup Study. Cancer Chemother Pharmacol 2002;50:37-45.
|
